Tools
Genetics: Inheritance Patterns
Introduction
The field of genetics originated in the 19th century with the pioneering work of Gregor Mendel, whose meticulous experiments on pea plants established fundamental principles of inheritance. Through systematic observation of traits, such as seed shape, flower color, and plant height, Mendel formulated 3 key laws: the Law of Dominance, the Law of Segregation, and the Law of Independent Assortment. These principles explain how discrete units of inheritance, now called "genes," pass from one generation to the next. Although Mendel’s work preceded recognition of DNA as the carrier of genetic information, modern biology confirms that phenotypic traits result from variations within this molecular framework.[1]
Mendel’s Law of Dominance states that different forms of a gene, called "alleles," can mask the expression of other alleles, resulting in dominant and recessive traits. The Law of Segregation states that allele pairs separate during gametogenesis, ensuring that each gamete carries only 1 allele for a given gene. Finally, the Law of Independent Assortment posits that alleles of different genes segregate independently during gamete formation. However, modern genetics recognizes exceptions to this principle, most notably genetic linkage, in which genes are located in proximity on the same chromosome.[2]
At the molecular level, individuals may carry identical (homozygous) or differing (heterozygous) alleles for a particular gene. Interactions between alleles produce varied inheritance patterns. Beyond complete dominance, inheritance patterns include incomplete dominance, in which a heterozygous genotype produces an intermediate phenotype, and codominance, in which both alleles are simultaneously and fully expressed.[3]
Inheritance patterns are generally categorized based on the chromosomal location of the responsible gene. In autosomal inheritance, the gene responsible for a trait or disorder resides on an autosome. Autosomal dominant conditions require only 1 copy of a pathogenic allele, whereas autosomal recessive conditions require 2 copies, with 1 inherited from each parent. In contrast, X-linked inheritance involves genes located on the X chromosome. Because males have only 1 X chromosome, X-linked recessive traits occur more frequently in males than in females. Together, these Mendelian patterns provide the clinical foundation for understanding how traits and monogenic (single-gene) disorders are transmitted within families.
Mechanism
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism
Autosomal Dominant Inheritance
In autosomal dominant conditions, a single mutant allele can produce a phenotype through several mechanisms. Haploinsufficiency occurs when a functional allele fails to produce sufficient gene product for normal function. Dominant-negative effects occur when a mutant protein interferes with the function of the normal wild-type protein. Gain-of-function mutations confer novel or constitutively active properties on the resulting protein.[4]
Autosomal dominant disorders can also arise de novo from sporadic mutations in parental gonads or the developing fetus. The recurrence risk for subsequent children of unaffected parents is typically less than 1%, whereas an affected individual has a 50% risk of transmitting the mutation to offspring.[5] Germline mosaicism can alter this risk when an unaffected parent carries the mutation in only a subset of germline cells, increasing the recurrence risk for another affected child to as high as 50%.[6]
Penetrance and transmission
Penetrance, defined as the percentage of individuals who inherit a disorder-related allele and express the associated phenotype, is critical in dominant disorders.[7] Reduced penetrance allows an individual to inherit a mutation without displaying symptoms while retaining the ability to transmit the mutation to offspring. Age-dependent conditions, which manifest only in adulthood, can also obscure a dominant family history when carriers die before the typical age of onset.
Affected individuals are typically heterozygous. With an unaffected partner, each child has a 50% chance of inheriting the disorder. These conditions typically demonstrate vertical transmission in pedigrees, affect both sexes equally, and rarely skip generations. When both parents are affected and heterozygous, each child has a 75% chance of inheriting the disorder. Individuals who are homozygously affected, with mutant alleles inherited from both parents, transmit the trait to 100% of their children and often exhibit a more severe phenotype.
Autosomal Recessive Inheritance
Autosomal recessive inheritance relies on haplosufficiency, in which a single normal allele produces sufficient protein to maintain physiological function. The phenotype manifests only when both alleles are nonfunctional. Autosomal recessive conditions often skip generations and demonstrate horizontal transmission, with affected individuals observed among siblings rather than across multiple generations. Affected individuals commonly have unaffected carrier parents and unaffected offspring.
Carrier dynamics and risks
Consanguinity, defined as mating between close relatives, significantly increases the likelihood of autosomal recessive conditions occurring within a family.[8] When both parents are carriers, each child has a 25% chance of being homozygous for the non-pathogenic allele and completely unaffected. The child has a 50% chance of inheriting 1 pathogenic allele and becoming a heterozygous, unaffected carrier. The remaining 25% results in a homozygous unaffected genotype.
Pseudodominance is an exception to the typical horizontal transmission pattern and occurs when an autosomal recessive trait appears in successive generations.[9] The pattern can arise when a homozygous affected individual has a child with a heterozygous carrier, resulting in a 50% chance that each child will be affected. Although the resulting pedigree can resemble vertical transmission of an autosomal dominant condition, other recessive features in the broader family history can help distinguish pseudodominance.
X-Linked Inheritance
X-linked inheritance is uniquely influenced by X inactivation. In heterozygous females, one X chromosome is randomly inactivated in each cell, resulting in mosaicism. The proportion of cells expressing the mutant versus normal allele contributes to substantial variation in phenotypic expression among female individuals.[10][11][12]
X-linked dominant inheritance
Both male and female individuals may be affected, although female individuals are affected more frequently and usually experience less severe disease. An affected male individual transmits the mutant allele to all daughters but none of his sons. An affected female individual has a 50% chance of transmitting the mutant allele to each child, regardless of sex. Many X-linked dominant disorders are lethal in male embryos early in development, resulting in the condition being observed almost exclusively among surviving female individuals.[13]
X-linked recessive inheritance
X-linked recessive disorders primarily affect males, although females may occasionally manifest these disorders because of skewed X inactivation, in which most active X chromosomes carry the mutation, homozygosity, or X-autosome translocations.[14] Because males have only 1 X chromosome, an affected male is hemizygous. An affected male individual transmits the mutation to 100% of daughters, who become carriers, and to 0% of sons. This pattern often produces a “Knight's move,” or diagonal, pattern of transmission, in which the disorder passes from an affected grandfather through an unaffected carrier daughter to an affected grandson. A carrier female individual and an unaffected male individual have a 50% chance of having affected sons and a 50% chance of having carrier daughters.
Testing
Identifying genetic disorders requires clinical awareness, a detailed family history, and targeted genetic testing. A thorough family pedigree remains an essential 1st step for clarifying inheritance patterns, assessing consanguinity risk, and guiding test selection.
Depending on the life stage and clinical presentation, testing modalities include preimplantation genetic testing for monogenic disorders, which allows couples undergoing in vitro fertilization to select embryos without a known pathogenic variant.[15] During pregnancy, chorionic villus sampling, amniocentesis, and noninvasive prenatal testing (NIPT) may be employed to assess fetal genetic status, with NIPT using maternal blood to estimate the risk of genetic abnormalities without an invasive procedure.[16] Postnatal diagnostic evaluation may involve targeted gene panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS). Gene panels may be utilized to evaluate defined phenotypes efficiently, whereas WES and WGS can help resolve complex or rare disorders.[17] Genetic counseling remains crucial throughout the evaluation process, particularly for populations at increased risk of specific genetic disorders, such as Tay-Sachs disease among individuals of Ashkenazi Jewish ancestry.
Clinical Significance
Various genetic disorders demonstrate how inheritance mechanisms influence clinical presentation, disease severity, and familial risk. Select examples are discussed below.
Autosomal dominant conditions, such as Marfan syndrome, caused by FBN1 variants that result in defective fibrillin, and tuberous sclerosis complex, caused by TSC1 or TSC2 variants that dysregulate the mTOR pathway, demonstrate how a single variant can produce severe multisystem disease.[18][19] A high proportion of tuberous sclerosis complex cases arise de novo, yet affected individuals retain a 50% risk of transmitting the variant to each offspring.[20]
Autosomal recessive disorders include cystic fibrosis, in which CFTR variants impair epithelial ion transport, and Tay-Sachs disease, in which HEXA variants cause progressive neurodegeneration.[21][22] Hemoglobinopathies, such as sickle cell disease, can cause anemia and reduced oxygen-carrying capacity.[23] Sickle cell disease also demonstrates incomplete dominance, as heterozygous carriers exhibit a mild cellular phenotype that confers partial protection against malaria.[24]
Many X-linked disorders present with neurological deficits because numerous X-chromosome genes contribute to brain function.[25][26] Fragile X syndrome, caused by a cytosine-guanine-guanine (CGG) repeat expansion in FMR1, is a leading inherited cause of intellectual disability.[27] Duchenne muscular dystrophy results from DMD variants that cause absent or severely deficient dystrophin, leading to progressive muscle degeneration during childhood.[28]
Determining whether a disorder is inherited or occurs de novo helps establish the appropriate risk assessment. Identifying the mode of transmission also guides reproductive counseling and targeted case management.
References
Gayon J. From Mendel to epigenetics: History of genetics. Comptes rendus biologies. 2016 Jul-Aug:339(7-8):225-30. doi: 10.1016/j.crvi.2016.05.009. Epub 2016 Jun 2 [PubMed PMID: 27263362]
Wolf JB, Ferguson-Smith AC, Lorenz A. Mendel's laws of heredity on his 200th birthday: What have we learned by considering exceptions? Heredity. 2022 Jul:129(1):1-3. doi: 10.1038/s41437-022-00552-y. Epub 2022 Jul 1 [PubMed PMID: 35778507]
Strome S, Bhalla N, Kamakaka R, Sharma U, Sullivan W. Clarifying Mendelian vs non-Mendelian inheritance. Genetics. 2024 Jul 8:227(3):. doi: 10.1093/genetics/iyae078. Epub [PubMed PMID: 38805696]
Billiard S, Castric V, Llaurens V. The integrative biology of genetic dominance. Biological reviews of the Cambridge Philosophical Society. 2021 Dec:96(6):2925-2942. doi: 10.1111/brv.12786. Epub 2021 Aug 12 [PubMed PMID: 34382317]
Acuna-Hidalgo R, Veltman JA, Hoischen A. New insights into the generation and role of de novo mutations in health and disease. Genome biology. 2016 Nov 28:17(1):241 [PubMed PMID: 27894357]
Martínez-Glez V, Tenorio J, Nevado J, Gordo G, Rodríguez-Laguna L, Feito M, de Lucas R, Pérez-Jurado LA, Ruiz Pérez VL, Torrelo A, Spinner NB, Happle R, Biesecker LG, Lapunzina P. A six-attribute classification of genetic mosaicism. Genetics in medicine : official journal of the American College of Medical Genetics. 2020 Nov:22(11):1743-1757. doi: 10.1038/s41436-020-0877-3. Epub 2020 Jul 14 [PubMed PMID: 32661356]
Kingdom R, Wright CF. Incomplete Penetrance and Variable Expressivity: From Clinical Studies to Population Cohorts. Frontiers in genetics. 2022:13():920390. doi: 10.3389/fgene.2022.920390. Epub 2022 Jul 25 [PubMed PMID: 35983412]
Darr A, Small N, Ahmad WI, Atkin K, Corry P, Modell B. Addressing key issues in the consanguinity-related risk of autosomal recessive disorders in consanguineous communities: lessons from a qualitative study of British Pakistanis. Journal of community genetics. 2016 Jan:7(1):65-79. doi: 10.1007/s12687-015-0252-2. Epub 2015 Sep 12 [PubMed PMID: 26363620]
Level 2 (mid-level) evidenceHoppe B, Danpure CJ, Rumsby G, Fryer P, Jennings PR, Blau N, Schubiger G, Neuhaus T, Leumann E. A vertical (pseudodominant) pattern of inheritance in the autosomal recessive disease primary hyperoxaluria type 1: lack of relationship between genotype, enzymic phenotype, and disease severity. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1997 Jan:29(1):36-44 [PubMed PMID: 9002528]
Level 3 (low-level) evidenceGendrel AV, Heard E. Fifty years of X-inactivation research. Development (Cambridge, England). 2011 Dec:138(23):5049-55. doi: 10.1242/dev.068320. Epub [PubMed PMID: 22069183]
Level 3 (low-level) evidenceSagie S, Monovich E. [MARY LYON (1925-2014) AND THE RANDOM INACTIVATION OF CHROMOSOME X]. Harefuah. 2016 Mar:155(3):140-4, 197 [PubMed PMID: 27305745]
Pavone V, Testa G, Gioitta Iachino S, Evola FR, Avondo S, Sessa G. Hypophosphatemic rickets: etiology, clinical features and treatment. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie. 2015 Feb:25(2):221-6. doi: 10.1007/s00590-014-1496-y. Epub 2014 Jun 24 [PubMed PMID: 24957364]
Franco B, Ballabio A. X-inactivation and human disease: X-linked dominant male-lethal disorders. Current opinion in genetics & development. 2006 Jun:16(3):254-9 [PubMed PMID: 16650755]
Level 3 (low-level) evidenceMigeon BR. X-linked diseases: susceptible females. Genetics in medicine : official journal of the American College of Medical Genetics. 2020 Jul:22(7):1156-1174. doi: 10.1038/s41436-020-0779-4. Epub 2020 Apr 14 [PubMed PMID: 32284538]
De Rycke M, Berckmoes V. Preimplantation Genetic Testing for Monogenic Disorders. Genes. 2020 Jul 31:11(8):. doi: 10.3390/genes11080871. Epub 2020 Jul 31 [PubMed PMID: 32752000]
Prior-de Castro C, Gómez-González C, Rodríguez-López R, Macher HC, Prenatal Diagnosis Commission and the Genetics Commission of the Spanish Society of Laboratory Medicine. Prenatal genetic diagnosis of monogenic diseases. Advances in laboratory medicine. 2023 Apr:4(1):28-51. doi: 10.1515/almed-2023-0024. Epub 2023 Mar 24 [PubMed PMID: 37359899]
Level 3 (low-level) evidenceBrancato D, Treccarichi S, Bruno F, Coniglio E, Vinci M, Saccone S, Calì F, Federico C. NGS Approaches in Clinical Diagnostics: From Workflow to Disease-Specific Applications. International journal of molecular sciences. 2025 Oct 1:26(19):. doi: 10.3390/ijms26199597. Epub 2025 Oct 1 [PubMed PMID: 41096862]
Bitterman AD, Sponseller PD. Marfan Syndrome: A Clinical Update. The Journal of the American Academy of Orthopaedic Surgeons. 2017 Sep:25(9):603-609. doi: 10.5435/JAAOS-D-16-00143. Epub [PubMed PMID: 28837453]
Salussolia CL, Klonowska K, Kwiatkowski DJ, Sahin M. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex. Annual review of genomics and human genetics. 2019 Aug 31:20():217-240. doi: 10.1146/annurev-genom-083118-015354. Epub 2019 Apr 24 [PubMed PMID: 31018109]
Man A, Di Scipio M, Grewal S, Suk Y, Trinari E, Ejaz R, Whitney R. The Genetics of Tuberous Sclerosis Complex and Related mTORopathies: Current Understanding and Future Directions. Genes. 2024 Mar 4:15(3):. doi: 10.3390/genes15030332. Epub 2024 Mar 4 [PubMed PMID: 38540392]
Level 3 (low-level) evidenceSosnay PR, Raraigh KS, Gibson RL. Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype. Pediatric clinics of North America. 2016 Aug:63(4):585-98. doi: 10.1016/j.pcl.2016.04.002. Epub [PubMed PMID: 27469177]
Ferreira CR, Gahl WA. Lysosomal storage diseases. Translational science of rare diseases. 2017 May 25:2(1-2):1-71. doi: 10.3233/TRD-160005. Epub 2017 May 25 [PubMed PMID: 29152458]
Vekilov PG. Sickle-cell haemoglobin polymerization: is it the primary pathogenic event of sickle-cell anaemia? British journal of haematology. 2007 Oct:139(2):173-84 [PubMed PMID: 17897293]
Level 3 (low-level) evidenceKariuki SN, Williams TN. Human genetics and malaria resistance. Human genetics. 2020 Jun:139(6-7):801-811. doi: 10.1007/s00439-020-02142-6. Epub 2020 Mar 4 [PubMed PMID: 32130487]
Martin HC, Gardner EJ, Samocha KE, Kaplanis J, Akawi N, Sifrim A, Eberhardt RY, Tavares ALT, Neville MDC, Niemi MEK, Gallone G, McRae J, Deciphering Developmental Disorders Study, Wright CF, FitzPatrick DR, Firth HV, Hurles ME. The contribution of X-linked coding variation to severe developmental disorders. Nature communications. 2021 Jan 27:12(1):627. doi: 10.1038/s41467-020-20852-3. Epub 2021 Jan 27 [PubMed PMID: 33504798]
Leitão E, Schröder C, Parenti I, Dalle C, Rastetter A, Kühnel T, Kuechler A, Kaya S, Gérard B, Schaefer E, Nava C, Drouot N, Engel C, Piard J, Duban-Bedu B, Villard L, Stegmann APA, Vanhoutte EK, Verdonschot JAJ, Kaiser FJ, Tran Mau-Them F, Scala M, Striano P, Frints SGM, Argilli E, Sherr EH, Elder F, Buratti J, Keren B, Mignot C, Héron D, Mandel JL, Gecz J, Kalscheuer VM, Horsthemke B, Piton A, Depienne C. Systematic analysis and prediction of genes associated with monogenic disorders on human chromosome X. Nature communications. 2022 Nov 2:13(1):6570. doi: 10.1038/s41467-022-34264-y. Epub 2022 Nov 2 [PubMed PMID: 36323681]
Level 1 (high-level) evidenceRaspa M, Wheeler A, Okoniewski KC, Edwards A, Scott S. Research Gaps in Fragile X Syndrome: An Updated Literature Review to Inform Clinical and Public Health Practice. Journal of developmental and behavioral pediatrics : JDBP. 2023 Jan 1:44(1):e56-e65. doi: 10.1097/DBP.0000000000001134. Epub 2022 Oct 11 [PubMed PMID: 36219479]
Cohn RD, Campbell KP. Molecular basis of muscular dystrophies. Muscle & nerve. 2000 Oct:23(10):1456-71 [PubMed PMID: 11003781]